Anavex Investors Have Until Nov. 30 to Seek Lead Plaintiff Role

Anavex Life Sciences Corp. investors who acquired securities during a period covered by a proposed class action have until Nov. 30, 2026, to ask a federal court for lead-plaintiff status. The proposed class covers investors who bought or acquired Anavex securities from Nov. 26, 2025, through Aug. 28, 2026. In a lawsuit filed in the U.S. District Court for the Southern District of New York, the plaintiffs allege that Anavex had inadequate controls and understated regulatory risks linked to alleged conduct by former Chief Executive Officer Christopher Missling. The plaintiffs also challenge Anavex’s statements about its business, operations and outlook, claiming they were misleading or lacked a reasonable basis. Mar.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.